Effects of Chronic Inflammation on the Human Body with Age

Chronic low-grade inflammation acts as a persistent signalling state rather than a distinct physical symptom, producing indirect damage that tracks with cardiovascular events, insulin resistance, muscle loss, and cognitive decline over decades. At Longevity Benchmark, we read the cohort studies and randomised trials behind these markers for the guides we publish here. The underlying process reflects an active switch-off mechanism that falters with age while inflammatory sources accumulate throughout the body.

Circulating inflammatory messengers do not destroy tissues overnight. Instead, continuous low-level signalling alters cellular function, impairs tissue repair, and accelerates chronic disease pathways across multiple organ systems. The immune components driving this quiet state include senescent cells releasing pro-inflammatory factors, visceral fat macrophages, and altered white blood cell populations.

Measurable Consequences of Persistent Inflammatory Signalling

Systemic chronic inflammation causes cumulative tissue damage across decades by sustaining low-grade immune signalling that impairs metabolic, vascular, and musculoskeletal function.

The damage is indirect. Unlike acute infections that produce immediate pain, heat, and swelling, systemic chronic inflammation operates below the threshold of physical perception. In a comprehensive review published in Nature Medicine, David Furman and colleagues documented that systemic chronic inflammation is characterized by damage-associated molecular patterns triggering low-grade, non-resolving immune activity. Rather than ending in healing and tissue repair, this persistent signalling produces collateral damage over time, including cellular oxidative stress.

The observational evidence linking chronic inflammation to age-related disease is strongest for metabolic syndrome, type 2 diabetes, and cardiovascular disease. The same review identified documented associations with non-alcoholic fatty liver disease, chronic kidney disease, hypertension, osteoporosis, sarcopenia, neurodegenerative disorders, and depression. However, whether inflammation causes age-related disease or merely serves as a predictive marker of biological ageing remains actively debated.

Longitudinal data from large human cohorts show that elevated inflammatory markers correlate with shortened life expectancy. In the Iowa 65+ Rural Health Study, Harris and colleagues followed 1,293 healthy, non-disabled older adults in the American Journal of Medicine over an average of 4.6 years. Participants in the highest quartile of interleukin-6 faced a relative risk of death of 1.9 compared to the lowest quartile. Participants in the highest quartile of C-reactive protein faced a relative risk of 1.6.

Individuals elevated on both interleukin-6 and C-reactive protein were 2.6 times more likely to die than those with low levels of both markers. This association remained independent of age, sex, smoking, diabetes, cardiovascular disease, body mass index, and white blood cell count. Despite these strong observational correlations, the authors of the Nature Medicine review emphasize that there are presently no standard clinical biomarkers for indicating the presence of health-damaging chronic inflammation.

Mechanisms of Active Resolution Failure in Ageing Tissues

Tissue resolution of inflammation is an active, programmed biochemical process driven by specialized pro-resolving mediators rather than a passive dilution of inflammatory signals.

The switch-off process relies on dedicated biochemistry. In a foundational review in Nature, Charles N. Serhan detailed how acute inflammatory responses undergo lipid-mediator class switching. Initiation relies on eicosanoids such as prostaglandins and leukotrienes derived from arachidonic acid. Resolution is actively governed by specialized pro-resolving mediators, which comprise the lipoxin, resolvin, protectin, and maresin families. These molecules derive from the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

These mediators act at nanomolar concentrations. Receptor-mediated actions occur in the picomolar to nanomolar range to stop human neutrophil migration into injured tissue. Specialized pro-resolving mediators promote the clearance of apoptotic neutrophils through efferocytosis and shift macrophages toward a reparative M2 phenotype. When resolution fails, prostaglandins and leukotrienes persist. That ongoing signalling leads to chronic inflammation and fibrosis.

Resolution programs falter as tissues age. In an experimental peritonitis model published in the Journal of Immunology, Hildur H. Arnardottir and colleagues demonstrated that aged mice exhibited delayed resolution of acute inflammation alongside reduced levels of specialized pro-resolving mediators. Administering the mediator precursor DHA accelerated tissue resolution in these aged mice, while nano-medicines carrying aspirin-triggered resolvins D1 and D3 reduced inflammatory cell counts by promoting efferocytosis. These animal findings illustrate the mechanical concept, but clinical trials verifying whether specialized pro-resolving mediator precursors restore resolution programs in older humans have not been established.

Biological Sources of Systemic Inflammatory Signals

Endogenous sources of inflammatory signalling multiply with advancing age, driven by senescent cells, expanding visceral fat, and a restructuring immune system.

Senescent cells represent a primary driver of the age-related secretory burden. In an extensive review in the Annual Review of Pathology, Jean-Philippe Coppé and colleagues described the senescence-associated secretory phenotype (SASP). Cells undergoing senescence arrest replication within 24 hours but require more than five days to develop a complete secretory profile. Once established, this secretory phenotype is largely irreversible.

The secretory phenotype releases a complex cocktail of signalling molecules. Interleukin-6 is the most prominent cytokine of the phenotype, regulated by persistent DNA-damage signalling through ATM and CHK2 kinases. The phenotype also secretes interleukin-1alpha, interleukin-1beta, interleukin-8, granulocyte-macrophage colony-stimulating factor, matrix metalloproteinases, and chemokines. Plasminogen activator activity rises more than 50-fold in senescent endothelial cells and fibroblasts. p53 actively restrains this secretory programme, so losing p53 enhances it.

Clearing senescent cells alters physical function in preclinical models. In a 2018 study in Nature Medicine, Ming Xu and colleagues showed that transplanting small numbers of senescent cells into young mice caused persistent physical dysfunction and spread senescence to host tissues. Treating human adipose tissue explants with the senolytic combination of dasatinib plus quercetin reduced naturally occurring senescent cells and their secretion of frailty-related pro-inflammatory cytokines. In naturally aged mice, the same combination increased post-treatment survival by 36 percent. However, Luigi Ferrucci and Elisa Fabbri noted in Nature Reviews Cardiology that no gold-standard biomarker of cellular senescence has been established.

Visceral adipose tissue acts as an additional inflammatory engine. In a study published in the Journal of Clinical Investigation, Stuart P. Weisberg and colleagues estimate that macrophages are less than 10 percent of adipose cells in lean mice and lean humans, but expand to nearly 40 percent in obese humans. In human adipose tissue, macrophage CD68 mRNA expression was 1.67 in obese individuals compared to 0.69 arbitrary units in lean individuals. Adipose tissue macrophages accounted for almost all adipose tumor necrosis factor-alpha (TNF-alpha) expression, whereas interleukin-6 was expressed across multiple adipose cell types.

Thymic Involution and Structural Remodeling of the Immune System

Ageing alters the cellular composition of the circulating immune system through an exponential reduction in thymic T-cell output combined with chronic viral antigenic pressure.

Thymic production begins declining early in human life. In a mathematical modeling study published in the Proceedings of the National Academy of Sciences, Siobhan Palmer and colleagues demonstrated that human thymic T-cell production declines exponentially with a half-life of 15.7 years. Males exhibit a steeper decline in T-cell receptor excision circles than females. Naive T-cell output falls by approximately two orders of magnitude between age 20 and age 70.

Total blood T-cell numbers remain stable despite falling thymic production. Peripheral clonal expansion maintains circulating cell counts, but this shifts the immune repertoire toward memory phenotypes. In a review of the immunology of ageing in Clinical Reviews in Allergy & Immunology, Tamas Fulop and colleagues described how naive T-cell loss restricts the immune repertoire. The authors placed macrophages at the center of the inflammaging concept as master coordinators of stress responses, noting that maintaining the energy-intensive M1 pro-inflammatory phenotype becomes harder with age while M2 regulatory phenotypes are less affected.

Cytomegalovirus (CMV) infection strongly modulates this immune remodeling. In a cohort study of 152 CMV-negative individuals published in the Journal of Immunology, Wertheimer and colleagues tracked that remodeling. Ageing produced an absolute loss of naive CD8 T cells but not naive CD4 T cells, and did not increase memory T-cell numbers. In a separate cohort of 239 subjects aged 21 to 96, an absolute increase in effector and effector-memory CD4 and CD8 cells appeared mainly in CMV-positive people with elevated anti-CMV antibody titres. In older adults, CMV-specific memory T cells can occupy up to 50 percent of the total memory T-cell pool, generating persistent immune stimulation.

Cardiovascular Evidence and the Causality Triangle

Clinical trials in cardiovascular disease confirm that targeted anti-inflammatory drugs can reduce vascular events, yet human genetics reveal that C-reactive protein is an indirect predictive marker rather than a causal driver.

CANTOS tested whether reducing inflammation without altering cholesterol lowers cardiovascular event rates. In this trial published in the New England Journal of Medicine, Paul M Ridker and colleagues randomized 10,061 patients with prior myocardial infarction and high-sensitivity C-reactive protein of 2 mg/L or higher to placebo or canakinumab, an interleukin-1beta monoclonal antibody. At 48 months, canakinumab reduced high-sensitivity C-reactive protein by 26 to 41 percentage points greater than placebo without changing lipid levels.

Over a median follow-up of 3.7 years, the primary endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death occurred at 4.50 events per 100 person-years in the placebo group, compared to 3.86 in the 150 mg canakinumab group. This represented a statistically significant 15 percent relative risk reduction (hazard ratio 0.85, 95 percent confidence interval 0.74 to 0.98). However, all-cause mortality was not significantly reduced (hazard ratio 0.94, 95 percent confidence interval 0.83 to 1.06), and canakinumab was associated with a higher incidence of fatal infection.

A prespecified secondary analysis, non-randomised and based on on-treatment response, reported that the clinical benefit tracked the achieved biomarker level. In a follow-up analysis in The Lancet, participants achieving an on-treatment high-sensitivity C-reactive protein below 2 mg/L experienced a 25 percent reduction in major adverse cardiovascular events and a 31 percent reduction in all-cause mortality. Participants who did not drop below 2 mg/L experienced no significant benefit. Similarly, an analysis in the European Heart Journal revealed that participants achieving on-treatment interleukin-6 below the median of 1.65 ng/L had a 32 percent reduction in major cardiovascular events and a 48 percent reduction in all-cause mortality.

Contrasting clinical trials highlight that the specific molecular target determines therapeutic success. In the COLCOT trial published in the New England Journal of Medicine, Jean-Claude Tardif and colleagues randomized 4,745 patients following a myocardial infarction to low-dose colchicine or placebo. Colchicine reduced the primary composite cardiovascular endpoint from 7.1 percent to 5.5 percent (hazard ratio 0.77, 95 percent confidence interval 0.61 to 0.96), though serious pneumonia was more frequent. Conversely, the CIRT trial published in the New England Journal of Medicine, evaluated low-dose methotrexate in 4,786 patients with stable atherosclerosis and diabetes or metabolic syndrome. Methotrexate failed to lower interleukin-1beta, interleukin-6, or C-reactive protein, and produced no reduction in cardiovascular events (hazard ratio 0.96).

Genetic Mendelian Randomisation and the Marker Paradox

Mendelian randomisation studies report that genetically raised C-reactive protein does not raise coronary risk, while genetically altered interleukin-6 receptor signalling does.

Large observational meta-analyses initially reported an association between C-reactive protein and coronary risk. In an analysis of 160,309 individuals across 54 prospective studies by the Emerging Risk Factors Collaboration, each 1-standard-deviation higher log C-reactive protein was associated with a fully adjusted risk ratio of 1.37 for coronary heart disease. The same analysis reported 1.27 for ischaemic stroke, 1.55 for vascular mortality, and 1.54 for non-vascular mortality. Because C-reactive protein predicted deaths from entirely unrelated diseases, the study authors concluded that its direct pathological relevance across such diverse disorders remained unclear.

Genetic studies resolved this ambiguity. In a comprehensive analysis of 194,418 participants published in the BMJ, the C-reactive Protein Coronary Heart Disease Genetics Collaboration evaluated variants in the CRP gene. While these genetic variants associated with up to 30 percent differences in circulating C-reactive protein concentration, they produced a combined risk ratio for coronary heart disease of 1.00 (95 percent confidence interval 0.90 to 1.13). Their combined risk ratio for coronary heart disease was 1.00 (95 percent confidence interval 0.90 to 1.13), and the authors conclude C-reactive protein "is unlikely to be even a modest causal factor in coronary heart disease".

Interleukin-6 receptor genetics produced the opposite result. In an 82-study analysis published in The Lancet, the IL6R Genetics Consortium analyzed the IL6R Asp358Ala gene variant across 125,222 participants. Each copy of the 358Ala allele lowered C-reactive protein by 7.5 percent, raised circulating interleukin-6 by 14.6 percent, and reduced coronary heart disease risk by 3.4 percent. These findings established that interleukin-6 receptor pathways are causally related to atherothrombosis, placing interleukin-6 receptor pathways in the causal chain for atherothrombosis and leaving C-reactive protein as a predictor of it.

Discrepancies in Type 2 Diabetes and Metabolic Risk

Prospective cohort studies associate systemic inflammation with incident type 2 diabetes, but adjusting for adiposity reveals conflicting results between individual biomarkers.

Circulating cytokines track closely with insulin resistance in observational cohorts. In the Women's Health Study published in JAMA, Aruna D. Pradhan and colleagues followed 27,628 women free of diabetes and cardiovascular disease at baseline. The crude relative risk of developing type 2 diabetes comparing the highest to lowest quartile was 7.5 for interleukin-6 and 15.7 for C-reactive protein. After adjusting for body mass index, smoking, exercise, and family history, interleukin-6 became statistically non-significant (relative risk 2.3, p = 0.07), while C-reactive protein remained strongly associated (relative risk 4.2, 95 percent confidence interval 1.5 to 12.0).

The Atherosclerosis Risk in Communities (ARIC) study observed directly opposing results. In an analysis published in Diabetes, Bruce B. Duncan and colleagues tracked 581 incident diabetes cases over nine years. Unadjusted hazard ratios comparing the top to bottom quartile ranged from 1.9 to 2.8 across inflammatory markers. After controlling for body mass index, waist-to-hip ratio, fasting glucose, and fasting insulin, C-reactive protein lost statistical significance. Only interleukin-6 remained an independent predictor of incident diabetes (hazard ratio 1.6, 95 percent confidence interval 1.01 to 2.7).

Demographic interactions further complicate metabolic risk tracking. In the ARIC analysis, an overall inflammatory score independently predicted diabetes in white participants but failed to predict diabetes in African American participants. The score predicted risk in non-smokers but not active smokers. Our evidence review on dietary patterns and inflammatory blood markers to understand how nutrition interacts with metabolic indices.

Muscle Strength Loss, Sarcopenia, and Frailty Associations

Inflammatory cytokines strongly correlate with declining muscle strength and functional mobility in older adults, though evidence separating strength loss from muscle mass loss remains divided.

Longitudinal cohorts identify muscle weakness as a key manifestation of chronic inflammation. In the Health ABC Study published in the Journals of Gerontology Series A, Marjolein Visser and colleagues evaluated 3,075 adults aged 70 to 79. Each standard deviation increase in interleukin-6 was associated with a 1.1 to 2.4 kg lower grip strength after adjusting for body fat, physical activity, and health status. Participants with elevations in both interleukin-6 and TNF-alpha had smaller cross-sectional muscle area and lower knee extensor strength, with the exception of white men.

Muscle strength appears far more sensitive to inflammatory damage than muscle mass. In the Longitudinal Aging Study Amsterdam published in the American Journal of Medicine, Laura A. Schaap and colleagues followed 986 older adults. Higher interleukin-6 and C-reactive protein conferred a 2- to 3-fold higher risk of losing more than 40 percent of muscle strength. However, no consistent association with sarcopenia (muscle mass loss) was found.

Mobility restrictions follow a similar threshold pattern. In the Iowa EPESE cohort published in the Journal of the American Geriatrics Society, older adults in the highest interleukin-6 tertile were 1.76 times more likely to develop mobility disability, with risk escalating rapidly beyond 2.5 pg/mL. In the Women's Health and Aging Study, published in the same journal, Ferrucci and colleagues reported that higher interleukin-6 increased mobility disability risk by 50 percent. When the researchers adjusted for changes in knee extensor strength, the statistical association disappeared. Muscle weakness mediated the functional decline.

The link between inflammation and clinical frailty displays a divide between cross-sectional and prospective studies. In the Cardiovascular Health Study published in the Archives of Internal Medicine, frail adults had mean C-reactive protein levels of 5.5 mg/L compared to 2.7 mg/L in robust adults. A systematic review of 35 studies published in Ageing Research Reviews by Soysal and colleagues confirmed large cross-sectional elevations in C-reactive protein and interleukin-6 among frail individuals. Yet across three longitudinal studies, neither baseline C-reactive protein (odds ratio 1.06) nor interleukin-6 (odds ratio 1.19) predicted incident frailty. Ferrucci and Fabbri noted that no randomised trial has demonstrated that reducing inflammation prevents clinical frailty.

Cognitive Decline and Neurodegenerative Patterns

Long-term epidemiological tracking connects elevated midlife inflammation with steeper cognitive decline, but individual markers yield divergent patterns across cohort studies.

Cognitive trajectories diverge across decades based on inflammatory exposure. In the Whitehall II cohort study published in Neurology, Archana Singh-Manoux and colleagues analyzed 5,217 civil servants over a 10-year period. Participants with high interleukin-6 exhibited a significantly greater 10-year decline in reasoning scores (-0.35 standard deviations versus -0.29 standard deviations) and 1.81 times higher odds of a meaningful drop on the Mini-Mental State Examination. In contrast, C-reactive protein was not associated with decline on any cognitive test. The combined inflammatory effect corresponded to an additional 3.9 years of cognitive ageing.

Midlife measurements capture extended trajectories. In the ARIC study published in Neurology, Keenan A. Walker and colleagues assessed 12,336 participants over 20 years. Each standard deviation increase in a midlife inflammatory composite score was associated with an additional 20-year cognitive decline of -0.035 standard deviations. Midlife C-reactive protein showed an independent association, with the highest quartile experiencing an 11.6 percent steeper cognitive decline than the lowest quartile, concentrated primarily in memory testing.

Clinical dementia risk demonstrates similar marker divergence. In a meta-analysis of seven prospective studies published in the Journals of Gerontology Series A, Koyama and colleagues found that elevated C-reactive protein was associated with a 45 percent increased risk of all-cause dementia. Interleukin-6 was associated with a 32 percent increase. When evaluating Alzheimer's disease specifically, C-reactive protein was weakly predictive (hazard ratio 1.21), while interleukin-6 showed no significant association (hazard ratio 1.06, 95 percent confidence interval 0.83 to 1.35). In the Framingham Heart Study published in Neurology, Zaldy S. Tan and colleagues found that higher peripheral blood mononuclear cell production of TNF-alpha and interleukin-1 conferred a more than twofold increased risk of incident Alzheimer's disease.

Acute Immune Responses Versus Low-Grade Systemic States

Acute inflammation and systemic chronic inflammation engage fundamentally different physiological triggers, molecular magnitudes, and clinical resolution timelines.

The molecular triggers separate the two states completely. As detailed by Furman and colleagues in Nature Medicine, acute inflammation is triggered by pathogen-associated molecular patterns during infections, or by damage-associated molecular patterns resulting from acute trauma. Systemic chronic inflammation is triggered by endogenous damage-associated molecular patterns, metabolic stress, and cellular debris without an active infectious agent.

The magnitude of the systemic response differs by several orders of magnitude. In a critical review in the Journal of Clinical Investigation, Mark B. Pepys and Gideon M. Hirschfield analyzed human C-reactive protein kinetics. In healthy young blood donors, median C-reactive protein is 0.8 mg/L, the 90th centile is 3.0 mg/L, and the 99th centile is 10 mg/L. During an acute bacterial infection, C-reactive protein can rise from under 50 micrograms/L to over 500 mg/L, representing a 10,000-fold increase.

Circulating dynamics are tightly regulated by hepatic synthesis. C-reactive protein passes 5 mg/L roughly 6 hours after an inflammatory stimulus and peaks near 48 hours. Its plasma half-life is constant at approximately 19 hours across both health and severe disease, meaning circulating blood concentrations reflect the hepatic rate of synthesis. Hepatocytes produce C-reactive protein under the transcriptional control of interleukin-6.

The Inflammaging Framework and Evolutionary Context

The concept of inflammaging describes an age-progressive increase in pro-inflammatory status that was originally formulated as an evolutionary trade-off rather than an inherently destructive flaw.

The terminology originated in the evolutionary biology of human ageing. In a 2000 paper published in the Annals of the New York Academy of Sciences, Claudio Franceschi and colleagues introduced the term inflamm-aging to describe the evolutionary perspective on immunosenescence. Over 1,000 scientific publications have since evaluated the concept. In their original framing, Franceschi held that inflammaging was neither harmful nor beneficial per se, representing an adaptive stress response that turned destructive only when containment thresholds were exceeded.

Modern reviews emphasize that the concept has frequently been distorted in commercial health communication. In their 2023 review in Clinical Reviews in Allergy & Immunology, Fulop and colleagues argued that inflammaging has been misconstrued as an exclusively detrimental phenomenon that must be eradicated. The macrophage sits at the center of the concept as the coordinator of cellular stress responses. Franceschi and colleagues also proposed the concept of anti-inflammaging, noting that healthy ageing and longevity reflect efficient anti-inflammatory networks as well as a lower propensity to mount inflammatory responses.

Clinical studies in long-lived cohorts support this dual-network view. Franceschi and colleagues report that interleukin-6 "is increased sometimes to extraordinarily high levels even in the case of centenarians," attributing their resistance to an anti-inflammatory network. Genetic research in over 2,000 Chinese centenarians linked an interleukin-6 gene variant (rs2069837) to extreme longevity, while the interleukin-6 promoter variant -174G>C enhances cytokine production. Fulop and colleagues describe inflammaging and immunosenescence as "the two sides of the same coin," in a "mutually maintained state where immunosenescence is induced by inflamm-aging and vice versa."

Interventional Boundaries and Validated Testing Priorities

Interventional trials show that while specific anti-inflammatory pathways alter clinical endpoints, lifestyle and pharmacological therapies produce narrow, context-dependent effects on inflammatory markers.

Lifestyle interventions do not lower inflammatory markers uniformly across all modalities. In an 18-month randomised trial published in the American Journal of Clinical Nutrition, Barbara J. Nicklas and colleagues evaluated 316 overweight older adults with osteoarthritis assigned to diet-induced weight loss, exercise training, or both. Diet-induced weight loss produced statistically significant reductions in C-reactive protein (p = 0.01), interleukin-6 (p = 0.009), and soluble TNF receptor 1 (p = 0.007). In contrast, exercise training alone had no statistically significant effect on any of these inflammatory markers, and no synergistic interaction occurred between diet and exercise.

Translational research into gut permeability illustrates the gap between rodent models and human physiology. Studies in germ-free mice published in Cell Host & Microbe show that germ-free animals do not display age-related cytokine increases, while co-housing them with older conventional mice drives inflammation. However, in their review in Nature Reviews Cardiology, Ferrucci and Fabbri stated plainly that no definitive evidence exists of increased gut permeability in older humans without overt gastrointestinal disease. Animal models cannot be treated as proven human reality.

Clinical risk stratification relies strictly on established venous cut-points. The Centers for Disease Control and Prevention and the American Heart Association classify high-sensitivity C-reactive protein into three population risk bands. Below 1 mg/L indicates low cardiovascular risk, 1 to 3 mg/L average risk, and above 3 mg/L high risk. Values above 10 mg/L are typically attributed to acute infection. In an analysis in Circulation, Amit Khera and colleagues cautioned that high-sensitivity C-reactive protein is significantly confounded by obesity, race, and sex. Mean levels were 1.63 mg/L in Caucasian participants versus 2.76 mg/L in African American participants, and 1.65 mg/L in men versus 2.51 mg/L in women.

Novel biological age markers offer alternative views of systemic immune ageing. In a study of 5,117 Europeans published in The Journals of Gerontology Series A, Jasminka Krištić and colleagues found that an index of three IgG glycans explained up to 58 percent of the variance in chronological age. That index outperformed telomere length.

If you have an acute illness, a fever, or a localized infection, a raised inflammatory marker is an appropriate immune response rather than a long-term trend, and it belongs with a clinician. The cohort evidence here is about persistent low-grade signalling, not about an acute response. Furthermore, a prospective double-blind randomised trial demonstrating that pharmacologically lowering systemic inflammatory markers extends human lifespan or prevents incident physical frailty in healthy older adults would change our assessment. If you want to evaluate your circulating markers with a doctor, review our guide to blood tests that measure inflammation or examine the clinical reference ranges in our breakdown of hsCRP testing.

Related

• hsCRP: chronic inflammation, measured
• Which blood test shows inflammation across acute and chronic illness
• CRP blood test dangerous level: ranges and acute results
• ESR vs C-reactive protein: interpreting disagreeing markers
• hs-CRP vs glycans for chronic inflammation
• Anti-inflammatory diet evidence and what blood markers measure